Delving into the Latest Updates on PM-8003 with Synapse

Overview

Basic Info

Drug Type

Trispecific antibody

Synonyms

PM 8003, PM8003

Target

PDL1 x TGF-β x VEGF

Action

inhibitors, modulators

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors), VEGF inhibitors(Vascular endothelial growth factor inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Biotheus, Inc.

Active Organization

Biotheus, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

单药I期：评价PM8003在晚期实体瘤受试者治疗中的安全性和耐受性。单药IIa期：初步评估PM8003单药治疗在多种特定晚期实体瘤受试者中的疗效。联合I期：评价PM8003联合用药的安全性和耐受性联合IIa期：初步评估PM8003联合用药的疗效

[Translation]

Phase I of single-agent study: evaluate the safety and tolerability of PM8003 in the treatment of subjects with advanced solid tumors. Phase IIa of single-agent study: preliminarily evaluate the efficacy of PM8003 monotherapy in subjects with various specific advanced solid tumors. Phase I of combined study: evaluate the safety and tolerability of PM8003 combined with other drugs Phase IIa of combined study: preliminarily evaluate the efficacy of PM8003 combined with other drugs

Start Date31 Aug 2021

Sponsor / Collaborator

Biotheus, Inc.

ChiCTR2100049391

/ SuspendedPhase 1IIT

Phase I clinical trial to evaluate the tolerability, safety, pharmacokinetic characteristics and primary efficacy of PM8003 injection in patients with advanced solid tumors and Phase IIa clinical trial to evaluate the primary efficacy of PM8003 injection in advanced solid tumors

Start Date16 Aug 2021

Sponsor / Collaborator-

100 Clinical Results associated with PM-8003

Login to view more data

100 Translational Medicine associated with PM-8003

Login to view more data

100 Patents (Medical) associated with PM-8003

Login to view more data

100 Deals associated with PM-8003

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 2	China	Biotheus, Inc.	31 Aug 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data